Lv7
3478 积分 2021-12-01 加入
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
2天前
已完结
A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants
2天前
已完结
Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial
2天前
已完结
Efficacy of Sentinel Cerebral Embolic Protection Device in Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials and Propensity Score-Matched Studies
15天前
已完结
A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten
17天前
已完结
Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period
17天前
已完结
Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center
17天前
已完结
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation
17天前
已完结
Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes
1个月前
已完结
皖公网安备34019202002308
